Dateline City: DURHAM, N.C. New Sizes Will Allow Physicians to Treat Broader Group of Patients with Bifurcation Disease DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced receipt of CE Mark for larger-diameter sizes of the Tryton Side Branch Stent System™ for the treatment of coronary artery disease. Launch of the …
Tryton Announces Enrollment of First U.S. Patient in Pivotal Study of Side Branch Stent
Dateline City: DURHAM, N.C. Study Is the First Randomized Multi-Center Bifurcation Trial in the United States DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced that the first U.S. patient has been enrolled in the pivotal trial to evaluate the Tryton Side Branch Stent System™ for the treatment of coronary artery …
Tryton Announces Enrollment of First Patient in U.S. Pivotal Study of Side Branch Stent
Dateline City: DURHAM, N.C. Study to Enroll 704 Patients At Up To 75 Centers in North America and Europe Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced that the first patient has been enrolled in the pivotal trial to evaluate the Tryton Side Branch Stent System™ for the treatment of coronary artery …
Tryton Announces Investigational Device Exemption Conditional Approval from FDA to Conduct U.S. Pivotal Study of Side Branch Stent
Dateline City: DURHAM, N.C. Study to Enroll 700 Patients At Up To 75 Centers in North America and Europe DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced U.S. Food and Drug Administration (FDA) conditional approval for an Investigational Device Exemption (IDE) application to initiate the pivotal trial to evaluate the …
Clinical Study Featuring Tryton Stent Wins Best Abstract Award at Italian Society of Interventional Cardiology National Congress (GISE) in Genoa, Italy
Dateline City: DURHAM, N.C. Live Case Transmission During Conference Demonstrates Ease-of-Use of Tryton Stent System DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced that an abstract reporting results from the company’s Tryton stent system was recognized as the best presented at the Italian Society of Interventional Cardiology National Congress (GISE) …
Tryton Announces First Patient Enrollment in E-Tryton Italy Registry of the Tryton Side Branch Stent System
Dateline City: DURHAM, N.C. Study To Assess Real-Life Clinical Results in 300 Patients With Bifurcation Disease in Italy DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced that the first patient has been enrolled in E-Tryton Italy, a registry study of the company’s Tryton Side Branch Stent™ System. E-Tryton Italy is …
Tryton Announces TCT Activities
Dateline City: DURHAM, N.C. Symposium to Feature Interim Six-Month Results from More Than 250 Patients Treated with Tryton Stent System DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced that the company will sponsor a symposium on Thursday, Sept. 23, 2010 during the Transcatheter Cardiovascular Therapeutics (TCT) 2010 conference in Washington, …
Tryton Completes $20 Million Financing To Accelerate U.S. Pivotal Trial
Dateline City: DURHAM, N.C. Strong Support from Current Investors and New Investor Arnerich Massena & Associates DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, today announced that the company has closed a $20 million Series D round of financing. Current investors PTV Sciences, RiverVest Venture Partners and Spray Venture Partners continue to provide …
Tryton Announces Launch in Several European and Eastern European Countries
Dateline City: DURHAM, N.C. Excellent Six-Month Clinical Results with Target Lesion Revascularization Rate of Less Than Four Percent DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced that the company has launched the Tryton Stent System in Switzerland, Sweden, Finland, Turkey, Hungary, Czech Republic, Slovakia and Latvia. “We are pleased to …
Tryton Announces First Implants in Israel
Dateline City: DURHAM, N.C. More Than 1,300 Patients Treated Worldwide with Tryton Stent System DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, announced that the company’s TRYTON Side Branch Stent™ System has been used in three cases in Israel for the first time. Yaron Almagor, M.D., director of the Interventional Cardiology and …